Compare ALG & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALG | PTGX |
|---|---|---|
| Founded | 1955 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 9.3B |
| IPO Year | 1996 | 2016 |
| Metric | ALG | PTGX |
|---|---|---|
| Price | $168.07 | $143.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | ★ $225.00 | $108.23 |
| AVG Volume (30 Days) | 134.0K | ★ 456.7K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.81% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 4.96 | 2.35 |
| Revenue | ★ $1,603,715,000.00 | N/A |
| Revenue This Year | $5.26 | $874.25 |
| Revenue Next Year | $3.97 | N/A |
| P/E Ratio | ★ $34.09 | $63.06 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $145.76 | $57.90 |
| 52 Week High | $219.88 | $160.81 |
| Indicator | ALG | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 53.04 | 52.79 |
| Support Level | $167.49 | $141.95 |
| Resistance Level | $172.44 | $160.81 |
| Average True Range (ATR) | 5.13 | 5.37 |
| MACD | 0.19 | -0.89 |
| Stochastic Oscillator | 55.70 | 36.38 |
Alamo Group Inc is engaged in the design, manufacture, and servicing of high-quality vegetation management and infrastructure maintenance equipment for governmental, industrial, and agricultural use. Its products include agricultural implements, tree and branch chippers, forestry/wood recycling equipment, street and parking lot sweepers, leaf and debris collection equipment, truck-mounted highway attenuator trucks, vacuum trucks, hydro-excavation equipment, telescopic boom excavators, snow removal equipment, etc. The company's reportable segments are Vegetation Management, which generates the maximum revenue, and Industrial Equipment. Geographically, the company generates maximum revenue from the United States, followed by Canada, France, the UK, Brazil, the Netherlands, and other regions.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.